AG˹ٷ

STOCK TITAN

[6-K] Ellomay Capital LTD Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Abacus Global Management, Inc. ("the Company") filed Amendment No. 1 to its Schedule TO to update documentation for its issuer tender offer and related consent solicitation covering the Company’s 20,623,395 outstanding warrants (11,723,395 public; 8,900,000 private placement).

Under the Offer, each warrant may be exchanged for 0.23 common shares (par $0.0001), implying the issuance of up to 4,743,381 new shares. Concurrently, the Company is seeking consents from at least 50 % of public-warrant holders to approve a Warrant Amendment that would allow the Company, after the offer closes, to mandatorily exchange any untendered warrants at a reduced ratio of 0.207 shares per warrant (10 % lower).

The warrants currently carry a $11.50 exercise price and trade on Nasdaq under the symbol ABLLW. By eliminating the warrants, management aims to simplify the capital structure, remove a potential overhang, and reduce future dilution that would occur if the warrants were exercised at the strike price. The filing expressly states that neither the Company nor its agents are making a recommendation to holders.

The amendment primarily replaces the prior Prospectus/Offer to Exchange and related letters originally filed on 30 June 2025 and updates Item 10 (financial statements). All other information in the original Schedule TO and incorporated Form S-4 remains unchanged.

Key considerations for investors:

  • Up to 4.74 million new shares will be issued immediately, creating direct dilution to existing common shareholders.
  • If holders do not tender and the Warrant Amendment is approved, they may be forced to accept the lower 0.207 ratio later.
  • The Company must secure consents from at least half of public-warrant holders for the amendment to become effective.
  • No cash is required; shares will be issued from authorized common stock.

The Schedule TO amendment does not modify offer economics or deadlines but refreshes the disclosure package to align with the Form S-4 amendment filed on 15 July 2025.

Abacus Global Management, Inc. ("la Società") ha presentato l'Emendamento n. 1 al proprio Schedule TO per aggiornare la documentazione relativa alla sua offerta pubblica di acquisto e alla relativa richiesta di consenso riguardante i 20.623.395 warrant in circolazione (11.723.395 pubblici; 8.900.000 in collocamento privato).

Secondo l'Offerta, ogni warrant può essere scambiato con 0,23 azioni ordinarie (valore nominale $0,0001), comportando l'emissione di un massimo di 4.743.381 nuove azioni. Contemporaneamente, la Società sta cercando il consenso di almeno il 50% dei detentori di warrant pubblici per approvare una Modifica dei Warrant che consentirebbe alla Società, dopo la chiusura dell'offerta, di scambiare obbligatoriamente eventuali warrant non consegnati a un rapporto ridotto di 0,207 azioni per warrant (10% in meno).

I warrant attualmente hanno un prezzo di esercizio di $11,50 e sono negoziati sul Nasdaq con il simbolo ABLLW. Eliminando i warrant, la direzione mira a semplificare la struttura del capitale, rimuovere un potenziale sovraccarico e ridurre la futura diluizione che si verificherebbe se i warrant venissero esercitati al prezzo di esercizio. Nel documento si specifica chiaramente che né la Società né i suoi agenti stanno fornendo una raccomandazione ai detentori.

L'emendamento sostituisce principalmente il Prospetto/Offerta di Scambio e le lettere correlate originariamente presentati il 30 giugno 2025 e aggiorna il Punto 10 (bilanci). Tutte le altre informazioni contenute nello Schedule TO originale e nel modulo S-4 incorporato restano invariate.

Punti chiave per gli investitori:

  • Saranno emesse immediatamente fino a 4,74 milioni di nuove azioni, causando una diluzione diretta per gli azionisti ordinari esistenti.
  • Se i detentori non aderiranno e la Modifica dei Warrant sarà approvata, potrebbero essere costretti ad accettare successivamente il rapporto inferiore di 0,207.
  • La Società deve ottenere il consenso di almeno la metà dei detentori di warrant pubblici affinché la modifica diventi efficace.
  • Non è richiesto alcun pagamento in contanti; le azioni saranno emesse dall'autorizzato capitale sociale ordinario.

L'emendamento allo Schedule TO non modifica le condizioni economiche o le scadenze dell'offerta, ma aggiorna il pacchetto informativo per allinearlo all'emendamento del modulo S-4 depositato il 15 luglio 2025.

Abacus Global Management, Inc. ("la Compañía") presentó la Enmienda N° 1 a su Schedule TO para actualizar la documentación de su oferta pública de adquisición y la solicitud de consentimiento relacionada que cubre los 20,623,395 warrants en circulación (11,723,395 públicos; 8,900,000 colocación privada).

Bajo la Oferta, cada warrant puede ser intercambiado por 0.23 acciones comunes (valor nominal $0.0001), lo que implica la emisión de hasta 4,743,381 nuevas acciones. Simultáneamente, la Compañía busca obtener el consentimiento de al menos el 50 % de los tenedores de warrants públicos para aprobar una Modificación de Warrant que permitiría a la Compañía, tras el cierre de la oferta, intercambiar obligatoriamente cualquier warrant no entregado a una tasa reducida de 0.207 acciones por warrant (10 % menor).

Los warrants actualmente tienen un precio de ejercicio de $11.50 y se negocian en Nasdaq bajo el símbolo ABLLW. Al eliminar los warrants, la dirección busca simplificar la estructura de capital, eliminar una posible sobrecarga y reducir la dilución futura que ocurriría si los warrants se ejercieran al precio de ejercicio. El documento aclara expresamente que ni la Compañía ni sus agentes están haciendo una recomendación a los tenedores.

La enmienda principalmente reemplaza el Prospecto/Oferta de Intercambio y las cartas relacionadas presentadas originalmente el 30 de junio de 2025 y actualiza el Ítem 10 (estados financieros). Toda la demás información del Schedule TO original y el Formulario S-4 incorporado permanece sin cambios.

Consideraciones clave para los inversores:

  • Se emitirán inmediatamente hasta 4.74 millones de nuevas acciones, generando una dilución directa para los accionistas comunes existentes.
  • Si los tenedores no entregan y se aprueba la Modificación de Warrant, podrían verse obligados a aceptar la tasa inferior de 0.207 más adelante.
  • La Compañía debe obtener consentimientos de al menos la mitad de los tenedores de warrants públicos para que la enmienda sea efectiva.
  • No se requiere efectivo; las acciones se emitirán del capital autorizado común.

La enmienda del Schedule TO no modifica la economía ni los plazos de la oferta, pero actualiza el paquete de divulgación para alinearlo con la enmienda del Formulario S-4 presentada el 15 de julio de 2025.

Abacus Global Management, Inc. ("회사")� 20,623,395개의 미결� 워런�(공개 11,723,395�; 사모 8,900,000�)� 대상으� 하는 발행� 공개 매수 � 관� 동의 요청 문서� 업데이트하기 위해 Schedule TO� 수정� 1호를 제출했습니다.

오퍼� 따라 � 워런트는 0.23 보통�(액면가 $0.0001)� 교환� � 있으�, 최대 4,743,381� 신규 주식� 발행� 예정입니�. 동시� 회사� 공개 워런� 보유자의 최소 50% 동의� 받아, 오퍼 종료 � 미제� 워런트를 강제 교환� � 있도� 하는 워런� 수정� 승인� 요청 중이�, � 경우 교환 비율은 워런트당 0.207�(10% 감소)� 낮아집니�.

현재 워런트의 행사가격은 $11.50이며, 나스닥에� ABLLW 심볼� 거래되고 있습니다. 워런트를 제거함으로써 경영진은 자본 구조� 단순화하�, 잠재� 부담을 해소하며, 행사가격으� 워런트가 행사� 경우 발생� 미래 희석 효과� 줄이� 합니�. 제출 문서에는 회사� 대리인� 보유자에� 권고� 하지 않는다고 명확� 명시되어 있습니다.

이번 수정안은 주로 2025� 6� 30� 최초 제출� 기존 투자설명�/교환 제안� � 관� 서신� 대체하�, 항목 10(재무제표)� 업데이트합니�. 원본 Schedule TO � 통합� Form S-4� 다른 모든 정보� 변경되지 않았습니�.

투자자들� 위한 주요 고려사항:

  • 최대 474� 주의 신규 주식� 즉시 발행되어 기존 보통� 주주에게 직접 희석� 발생합니�.
  • 보유자가 제출하지 않고 워런� 수정안이 승인되면, 이후 낮은 0.207 비율� 강제� 수용해야 � � 있습니다.
  • 수정� 발효� 위해서는 공개 워런� 보유자의 절반 이상 동의가 필요합니�.
  • 현금은 필요 없으�, 승인� 보통주에� 주식� 발행됩니�.

Schedule TO 수정안은 오퍼� 경제 조건이나 마감일을 변경하지 않으�, 2025� 7� 15� 제출� Form S-4 수정안에 맞춰 공시 자료� 갱신� 것입니다.

Abacus Global Management, Inc. ("la Société") a déposé l'Amendement n°1 à son Schedule TO afin de mettre à jour la documentation relative à son offre publique d'achat de titres émis et à la sollicitation de consentement associée concernant les 20 623 395 bons de souscription en circulation (11 723 395 publics ; 8 900 000 en placement privé).

Dans le cadre de l'Offre, chaque bon de souscription peut être échangé contre 0,23 actions ordinaires (valeur nominale de 0,0001 $), ce qui implique l'émission jusqu'à 4 743 381 nouvelles actions. Parallèlement, la Société recherche le consentement d'au moins 50 % des détenteurs publics de bons pour approuver un Amendement des Bons qui permettrait à la Société, après la clôture de l'offre, d'échanger de manière obligatoire tous les bons non présentés à un ratio réduit de 0,207 actions par bon (soit 10 % de moins).

Les bons ont actuellement un prix d'exercice de 11,50 $ et sont négociés sur le Nasdaq sous le symbole ABLLW. En éliminant les bons, la direction vise à simplifier la structure du capital, à supprimer un éventuel surplomb et à réduire la dilution future qui surviendrait si les bons étaient exercés au prix d'exercice. Le dépôt précise expressément que ni la Société ni ses agents ne font de recommandation aux détenteurs.

L'amendement remplace principalement le Prospectus/Offre d'Échange et les lettres associées déposés initialement le 30 juin 2025 et met à jour l'Item 10 (états financiers). Toutes les autres informations du Schedule TO original et du formulaire S-4 incorporé restent inchangées.

Points clés pour les investisseurs :

  • Jusqu'à 4,74 millions de nouvelles actions seront émises immédiatement, entraînant une dilution directe pour les actionnaires ordinaires existants.
  • Si les détenteurs ne présentent pas leurs bons et que l'Amendement est approuvé, ils pourraient être contraints d'accepter ultérieurement le ratio inférieur de 0,207.
  • La Société doit obtenir le consentement d'au moins la moitié des détenteurs publics de bons pour que l'amendement prenne effet.
  • Aucun paiement en espèces n'est requis ; les actions seront émises à partir du capital social autorisé.

L'amendement au Schedule TO ne modifie pas les conditions économiques ni les échéances de l'offre, mais actualise le dossier d'information pour l'aligner avec l'amendement du formulaire S-4 déposé le 15 juillet 2025.

Abacus Global Management, Inc. ("das Unternehmen") hat Nachtrag Nr. 1 zu seinem Schedule TO eingereicht, um die Dokumentation für sein ٳٱԳٱ-ÜԲ󳾱𲹲Բdz und die damit verbundene Zustimmungseinholung bezüglich der 20.623.395 ausstehenden Warrants (11.723.395 öffentlich; 8.900.000 Privatplatzierung) zu aktualisieren.

Im Rahmen des Angebots kann jeder Warrant gegen 0,23 Stammaktien (Nennwert $0,0001) eingetauscht werden, was die Ausgabe von bis zu 4.743.381 neuen Aktien impliziert. Gleichzeitig sucht das Unternehmen Zustimmungen von mindestens 50 % der öffentlichen Warrant-Inhaber, um eine ²Գ-ÄԻܲԲ zu genehmigen, die es dem Unternehmen nach Abschluss des Angebots ermöglichen würde, nicht eingereichte Warrants zwangsweise zu tauschen � und zwar zu einem reduzierten Verhältnis von 0,207 Aktien pro Warrant (10 % weniger).

Die Warrants haben derzeit einen Ausübungspreis von 11,50 $ und werden an der Nasdaq unter dem Symbol ABLLW gehandelt. Durch die Eliminierung der Warrants möchte das Management die Kapitalstruktur vereinfachen, eine potenzielle Belastung entfernen und die zukünftige Verwässerung reduzieren, die entstehen würde, wenn die Warrants zum Ausübungspreis ausgeübt würden. In der Einreichung wird ausdrücklich darauf hingewiesen, dass weder das Unternehmen noch seine Vertreter eine Empfehlung an die Inhaber aussprechen.

Der Nachtrag ersetzt hauptsächlich den zuvor eingereichten Prospekt/Umtauschangebot und die zugehörigen Schreiben vom 30. Juni 2025 und aktualisiert Punkt 10 (Finanzberichte). Alle anderen Informationen im ursprünglichen Schedule TO und im eingegliederten Formular S-4 bleiben unverändert.

Wichtige Überlegungen für Investoren:

  • Bis zu 4,74 Millionen neue Aktien werden sofort ausgegeben, was zu einer direkten Verwässerung der bestehenden Stammaktionäre führt.
  • Wenn Inhaber nicht bieten und die ²Գ-ÄԻܲԲ genehmigt wird, könnten sie später gezwungen sein, das niedrigere Verhältnis von 0,207 zu akzeptieren.
  • Das Unternehmen muss die Zustimmung von mindestens der Hälfte der öffentlichen Warrant-Inhaber erhalten, damit die Änderung wirksam wird.
  • Es ist kein Bargeld erforderlich; die Aktien werden aus dem genehmigten Stammkapital ausgegeben.

Der Nachtrag zum Schedule TO ändert weder die wirtschaftlichen Bedingungen noch die Fristen des Angebots, sondern aktualisiert das Offenlegungspaket, um es mit dem am 15. Juli 2025 eingereichten Nachtrag zum Formular S-4 in Einklang zu bringen.

Positive
  • Simplifies capital structure by removing up to 20.6 M warrants that could otherwise convert at $11.50.
  • Reduces future earnings dilution tied to warrant exercise, potentially improving valuation multiples.
  • No cash outlay; transaction executed with authorized shares, preserving liquidity.
Negative
  • Immediate dilution: issuance of up to 4.74 M new shares lowers existing shareholder ownership.
  • Coercive fallback ratio: untendered holders face a lower 0.207 exchange if amendment passes.
  • Approval uncertainty: 50 % public-warrant consent threshold must be met for the amendment to proceed.

Insights

TL;DR: Retiring 20.6 M warrants via 0.23-share exchange cuts overhang; 4.7 M-share dilution modestly positive overall.

The offer converts an out-of-the-money instrument (strike $11.50) into equity at a fixed 0.23 ratio, equating to roughly 2.3 shares per 10 warrants. Eliminating the warrants reduces future earnings dilution and volatility tied to warrant pricing, which can make the common stock more attractive to institutional investors. The immediate issuance of 4.74 M shares represents dilution of only the incremental difference between the current exchange and the higher potential dilution if warrants were ultimately exercised. Consequently, while near-term EPS impact is negative, the net present value could be accretive if the stock trades meaningfully below the $11.50 exercise price. Rating: modestly positive.

TL;DR: Consent solicitation gives Board power to force exchange; governance impact neutral but warrants scrutiny.

The dual-track structure—voluntary tender plus consent solicitation—offers holders choice yet pressures non-tendering investors via a 10 % worse fallback ratio. Requiring 50 % approval aligns with Warrant Agreement terms, mitigating coercion claims. Disclosures outline director and officer interests and explicitly withhold recommendations, adhering to Rule 13e-4. Governance risk appears limited, but investors should monitor participation levels and potential conflicts if insiders hold sizable warrants.

Abacus Global Management, Inc. ("la Società") ha presentato l'Emendamento n. 1 al proprio Schedule TO per aggiornare la documentazione relativa alla sua offerta pubblica di acquisto e alla relativa richiesta di consenso riguardante i 20.623.395 warrant in circolazione (11.723.395 pubblici; 8.900.000 in collocamento privato).

Secondo l'Offerta, ogni warrant può essere scambiato con 0,23 azioni ordinarie (valore nominale $0,0001), comportando l'emissione di un massimo di 4.743.381 nuove azioni. Contemporaneamente, la Società sta cercando il consenso di almeno il 50% dei detentori di warrant pubblici per approvare una Modifica dei Warrant che consentirebbe alla Società, dopo la chiusura dell'offerta, di scambiare obbligatoriamente eventuali warrant non consegnati a un rapporto ridotto di 0,207 azioni per warrant (10% in meno).

I warrant attualmente hanno un prezzo di esercizio di $11,50 e sono negoziati sul Nasdaq con il simbolo ABLLW. Eliminando i warrant, la direzione mira a semplificare la struttura del capitale, rimuovere un potenziale sovraccarico e ridurre la futura diluizione che si verificherebbe se i warrant venissero esercitati al prezzo di esercizio. Nel documento si specifica chiaramente che né la Società né i suoi agenti stanno fornendo una raccomandazione ai detentori.

L'emendamento sostituisce principalmente il Prospetto/Offerta di Scambio e le lettere correlate originariamente presentati il 30 giugno 2025 e aggiorna il Punto 10 (bilanci). Tutte le altre informazioni contenute nello Schedule TO originale e nel modulo S-4 incorporato restano invariate.

Punti chiave per gli investitori:

  • Saranno emesse immediatamente fino a 4,74 milioni di nuove azioni, causando una diluzione diretta per gli azionisti ordinari esistenti.
  • Se i detentori non aderiranno e la Modifica dei Warrant sarà approvata, potrebbero essere costretti ad accettare successivamente il rapporto inferiore di 0,207.
  • La Società deve ottenere il consenso di almeno la metà dei detentori di warrant pubblici affinché la modifica diventi efficace.
  • Non è richiesto alcun pagamento in contanti; le azioni saranno emesse dall'autorizzato capitale sociale ordinario.

L'emendamento allo Schedule TO non modifica le condizioni economiche o le scadenze dell'offerta, ma aggiorna il pacchetto informativo per allinearlo all'emendamento del modulo S-4 depositato il 15 luglio 2025.

Abacus Global Management, Inc. ("la Compañía") presentó la Enmienda N° 1 a su Schedule TO para actualizar la documentación de su oferta pública de adquisición y la solicitud de consentimiento relacionada que cubre los 20,623,395 warrants en circulación (11,723,395 públicos; 8,900,000 colocación privada).

Bajo la Oferta, cada warrant puede ser intercambiado por 0.23 acciones comunes (valor nominal $0.0001), lo que implica la emisión de hasta 4,743,381 nuevas acciones. Simultáneamente, la Compañía busca obtener el consentimiento de al menos el 50 % de los tenedores de warrants públicos para aprobar una Modificación de Warrant que permitiría a la Compañía, tras el cierre de la oferta, intercambiar obligatoriamente cualquier warrant no entregado a una tasa reducida de 0.207 acciones por warrant (10 % menor).

Los warrants actualmente tienen un precio de ejercicio de $11.50 y se negocian en Nasdaq bajo el símbolo ABLLW. Al eliminar los warrants, la dirección busca simplificar la estructura de capital, eliminar una posible sobrecarga y reducir la dilución futura que ocurriría si los warrants se ejercieran al precio de ejercicio. El documento aclara expresamente que ni la Compañía ni sus agentes están haciendo una recomendación a los tenedores.

La enmienda principalmente reemplaza el Prospecto/Oferta de Intercambio y las cartas relacionadas presentadas originalmente el 30 de junio de 2025 y actualiza el Ítem 10 (estados financieros). Toda la demás información del Schedule TO original y el Formulario S-4 incorporado permanece sin cambios.

Consideraciones clave para los inversores:

  • Se emitirán inmediatamente hasta 4.74 millones de nuevas acciones, generando una dilución directa para los accionistas comunes existentes.
  • Si los tenedores no entregan y se aprueba la Modificación de Warrant, podrían verse obligados a aceptar la tasa inferior de 0.207 más adelante.
  • La Compañía debe obtener consentimientos de al menos la mitad de los tenedores de warrants públicos para que la enmienda sea efectiva.
  • No se requiere efectivo; las acciones se emitirán del capital autorizado común.

La enmienda del Schedule TO no modifica la economía ni los plazos de la oferta, pero actualiza el paquete de divulgación para alinearlo con la enmienda del Formulario S-4 presentada el 15 de julio de 2025.

Abacus Global Management, Inc. ("회사")� 20,623,395개의 미결� 워런�(공개 11,723,395�; 사모 8,900,000�)� 대상으� 하는 발행� 공개 매수 � 관� 동의 요청 문서� 업데이트하기 위해 Schedule TO� 수정� 1호를 제출했습니다.

오퍼� 따라 � 워런트는 0.23 보통�(액면가 $0.0001)� 교환� � 있으�, 최대 4,743,381� 신규 주식� 발행� 예정입니�. 동시� 회사� 공개 워런� 보유자의 최소 50% 동의� 받아, 오퍼 종료 � 미제� 워런트를 강제 교환� � 있도� 하는 워런� 수정� 승인� 요청 중이�, � 경우 교환 비율은 워런트당 0.207�(10% 감소)� 낮아집니�.

현재 워런트의 행사가격은 $11.50이며, 나스닥에� ABLLW 심볼� 거래되고 있습니다. 워런트를 제거함으로써 경영진은 자본 구조� 단순화하�, 잠재� 부담을 해소하며, 행사가격으� 워런트가 행사� 경우 발생� 미래 희석 효과� 줄이� 합니�. 제출 문서에는 회사� 대리인� 보유자에� 권고� 하지 않는다고 명확� 명시되어 있습니다.

이번 수정안은 주로 2025� 6� 30� 최초 제출� 기존 투자설명�/교환 제안� � 관� 서신� 대체하�, 항목 10(재무제표)� 업데이트합니�. 원본 Schedule TO � 통합� Form S-4� 다른 모든 정보� 변경되지 않았습니�.

투자자들� 위한 주요 고려사항:

  • 최대 474� 주의 신규 주식� 즉시 발행되어 기존 보통� 주주에게 직접 희석� 발생합니�.
  • 보유자가 제출하지 않고 워런� 수정안이 승인되면, 이후 낮은 0.207 비율� 강제� 수용해야 � � 있습니다.
  • 수정� 발효� 위해서는 공개 워런� 보유자의 절반 이상 동의가 필요합니�.
  • 현금은 필요 없으�, 승인� 보통주에� 주식� 발행됩니�.

Schedule TO 수정안은 오퍼� 경제 조건이나 마감일을 변경하지 않으�, 2025� 7� 15� 제출� Form S-4 수정안에 맞춰 공시 자료� 갱신� 것입니다.

Abacus Global Management, Inc. ("la Société") a déposé l'Amendement n°1 à son Schedule TO afin de mettre à jour la documentation relative à son offre publique d'achat de titres émis et à la sollicitation de consentement associée concernant les 20 623 395 bons de souscription en circulation (11 723 395 publics ; 8 900 000 en placement privé).

Dans le cadre de l'Offre, chaque bon de souscription peut être échangé contre 0,23 actions ordinaires (valeur nominale de 0,0001 $), ce qui implique l'émission jusqu'à 4 743 381 nouvelles actions. Parallèlement, la Société recherche le consentement d'au moins 50 % des détenteurs publics de bons pour approuver un Amendement des Bons qui permettrait à la Société, après la clôture de l'offre, d'échanger de manière obligatoire tous les bons non présentés à un ratio réduit de 0,207 actions par bon (soit 10 % de moins).

Les bons ont actuellement un prix d'exercice de 11,50 $ et sont négociés sur le Nasdaq sous le symbole ABLLW. En éliminant les bons, la direction vise à simplifier la structure du capital, à supprimer un éventuel surplomb et à réduire la dilution future qui surviendrait si les bons étaient exercés au prix d'exercice. Le dépôt précise expressément que ni la Société ni ses agents ne font de recommandation aux détenteurs.

L'amendement remplace principalement le Prospectus/Offre d'Échange et les lettres associées déposés initialement le 30 juin 2025 et met à jour l'Item 10 (états financiers). Toutes les autres informations du Schedule TO original et du formulaire S-4 incorporé restent inchangées.

Points clés pour les investisseurs :

  • Jusqu'à 4,74 millions de nouvelles actions seront émises immédiatement, entraînant une dilution directe pour les actionnaires ordinaires existants.
  • Si les détenteurs ne présentent pas leurs bons et que l'Amendement est approuvé, ils pourraient être contraints d'accepter ultérieurement le ratio inférieur de 0,207.
  • La Société doit obtenir le consentement d'au moins la moitié des détenteurs publics de bons pour que l'amendement prenne effet.
  • Aucun paiement en espèces n'est requis ; les actions seront émises à partir du capital social autorisé.

L'amendement au Schedule TO ne modifie pas les conditions économiques ni les échéances de l'offre, mais actualise le dossier d'information pour l'aligner avec l'amendement du formulaire S-4 déposé le 15 juillet 2025.

Abacus Global Management, Inc. ("das Unternehmen") hat Nachtrag Nr. 1 zu seinem Schedule TO eingereicht, um die Dokumentation für sein ٳٱԳٱ-ÜԲ󳾱𲹲Բdz und die damit verbundene Zustimmungseinholung bezüglich der 20.623.395 ausstehenden Warrants (11.723.395 öffentlich; 8.900.000 Privatplatzierung) zu aktualisieren.

Im Rahmen des Angebots kann jeder Warrant gegen 0,23 Stammaktien (Nennwert $0,0001) eingetauscht werden, was die Ausgabe von bis zu 4.743.381 neuen Aktien impliziert. Gleichzeitig sucht das Unternehmen Zustimmungen von mindestens 50 % der öffentlichen Warrant-Inhaber, um eine ²Գ-ÄԻܲԲ zu genehmigen, die es dem Unternehmen nach Abschluss des Angebots ermöglichen würde, nicht eingereichte Warrants zwangsweise zu tauschen � und zwar zu einem reduzierten Verhältnis von 0,207 Aktien pro Warrant (10 % weniger).

Die Warrants haben derzeit einen Ausübungspreis von 11,50 $ und werden an der Nasdaq unter dem Symbol ABLLW gehandelt. Durch die Eliminierung der Warrants möchte das Management die Kapitalstruktur vereinfachen, eine potenzielle Belastung entfernen und die zukünftige Verwässerung reduzieren, die entstehen würde, wenn die Warrants zum Ausübungspreis ausgeübt würden. In der Einreichung wird ausdrücklich darauf hingewiesen, dass weder das Unternehmen noch seine Vertreter eine Empfehlung an die Inhaber aussprechen.

Der Nachtrag ersetzt hauptsächlich den zuvor eingereichten Prospekt/Umtauschangebot und die zugehörigen Schreiben vom 30. Juni 2025 und aktualisiert Punkt 10 (Finanzberichte). Alle anderen Informationen im ursprünglichen Schedule TO und im eingegliederten Formular S-4 bleiben unverändert.

Wichtige Überlegungen für Investoren:

  • Bis zu 4,74 Millionen neue Aktien werden sofort ausgegeben, was zu einer direkten Verwässerung der bestehenden Stammaktionäre führt.
  • Wenn Inhaber nicht bieten und die ²Գ-ÄԻܲԲ genehmigt wird, könnten sie später gezwungen sein, das niedrigere Verhältnis von 0,207 zu akzeptieren.
  • Das Unternehmen muss die Zustimmung von mindestens der Hälfte der öffentlichen Warrant-Inhaber erhalten, damit die Änderung wirksam wird.
  • Es ist kein Bargeld erforderlich; die Aktien werden aus dem genehmigten Stammkapital ausgegeben.

Der Nachtrag zum Schedule TO ändert weder die wirtschaftlichen Bedingungen noch die Fristen des Angebots, sondern aktualisiert das Offenlegungspaket, um es mit dem am 15. Juli 2025 eingereichten Nachtrag zum Formular S-4 in Einklang zu bringen.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2025

 

Commission File Number: 001-35284

 

Ellomay Capital Ltd.

(Translation of registrant’s name into English)

 

18 Rothschild Blvd., Tel Aviv 6688121, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

 

 

 

THIS FORM 6-K IS HEREBY INCORPORATED BY REFERENCE INTO THE REGISTRANT’S REGISTRATION STATEMENTS ON FORM F-3 (NOS. 333-199696 AND 333-144171) AND FORM S-8 (NOS. 333-187533, 333-102288 AND 333-92491), AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS SUBMITTED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED.

 

Update in connection with Exercise of Right of First Refusal for Dorad Energy Ltd. Shares

 

Ellomay Capital Ltd. (the “Company”), hereby provides an update in connection with the exercise of a right of first refusal for 7.5% of the outstanding shares of Dorad Energy Ltd. (“Dorad”) by Ellomay Luzon Energy Infrastructures Ltd. (“Ellomay Luzon Energy”) and following the Company’s immediate reports on Form 6-K submitted to the Securities and Exchange Commission on March 31, 2025, April 7, 2025, May 31, 2025, June 24, 2025, June 30, 2025, July 2, 2025 and July 14, 2025.

 

The Company hereby updates that on July 14, 2025 the transfer of 10% of Dorad’s shares to The Phoenix Insurance Company Ltd. and its affiliates (together, “The Phoenix”) was consummated. Therefore, the conditions to closing for the sale of 7.5% of Dorad’s shares to Ellomay Luzon Energy are fulfilled. As previously reported, the deadline for consummation of the purchase of Dorad’s shares in connection with the exercise of a right of first refusal is July 22, 2025. As noted in previous filings of the Company, Ellomay Luzon Energy previously notified the selling shareholder that Ellomay Luzon Energy maintains its right to purchase all the shares offered under the right of first refusal should the sale of 7.5% of Dorad’s shares to Edelcom Ltd. (the other Dorad shareholder that exercised its right of first refusal) not be consummated for any reason.

 

Information Relating to Forward-Looking Statements

 

This report contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this report regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words “estimate,” “will,” “project,” “intend,” “expect,” “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the Company’s forward-looking statements, including delays in the closing of the sale of Dorad’s shares, the non-fulfillment of any of the conditions to closing, changes in market conditions, inability to receive required regulatory approvals, the impact of the war and hostilities in Israel, Gaza and Iran, changes in electricity prices and demand, regulatory changes, including extension of current or approval of new rules and regulations increasing the operating expenses of manufacturers of renewable energy in Spain, increases in interest rates and inflation, changes in the supply and prices of resources required for the operation of the Company’s facilities (such as waste and natural gas) and in the price of oil, the impact of the continued military conflict between Russia and Ukraine, technical and other disruptions in the operations or construction of the power plants owned by the Company and general market, political and economic conditions in the countries in which the Company operates, including Israel, Spain, Italy and the United States. These and other risks and uncertainties associated with the Company’s business are described in greater detail in the filings the Company makes from time to time with the Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

1

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Ellomay Capital Ltd.
   
  By: /s/ Ran Fridrich
    Ran Fridrich
    Chief Executive Officer and Director

 

Dated: July 15, 2025

 

 

2

 

FAQ

What is Abacus Global Management (ABLLW) offering to warrant holders?

Holders may exchange each warrant for 0.23 common shares under the tender offer.

How many warrants and shares are involved in the exchange?

The offer covers 20,623,395 warrants and would issue up to 4,743,381 common shares.

What happens if the Warrant Amendment is approved?

Any warrants outstanding after the offer could be forcibly exchanged at 0.207 shares per warrant, a 10 % lower ratio.

What level of consent is needed to adopt the Warrant Amendment?

50 % of the outstanding public warrants must consent for the amendment to become effective.

Does Abacus recommend that holders tender their warrants?

No. The filing states that neither the Company nor its agents make any recommendation regarding tendering.
Ellomay Cap

NYSE:ELLO

ELLO Rankings

ELLO Latest News

ELLO Latest SEC Filings

ELLO Stock Data

228.90M
6.63M
50.32%
23.74%
0.01%
Utilities - Renewable
Utilities
Israel
Tel Aviv